Main Products/ Services/ Pipelines & Platforms
RCEVI can provide customized one-stop solution for virus research before preclinical trial. Service items: virus detection, virus isolation, antiviral or vaccine efficacy evaluation, high-throughput antiviral screening, etc. In vitro model: plaque assay, plaque reduction assay, neutralization assay, hemagglutination inhibition (HI) assay, RT-QPCR, ELISA, cytotoxicity, etc. In vivo model: Transgenic mouse model for virus challenge, in vivo imaging system (IVIS), etc. Pathogens: Respiratory viruses (e.g., coronavirus, influenza virus, RSV, parainfluenzavirus and others), Enteroviruses (e.g., EV-A71, EV-D68, coxsackievirus and others), Arbovirus (e.g., dengue virus, ZIKA virus and others), Enteric viruses (e.g., norovirus, rotavirus and others) Facilities: BSL-2, ABSL-2, BSL-3, ABSL-3 RCEVI also has a strong research team devoting to virus research, the representative publications and patents are listed at the following link: https://rceviweb.wixsite.com/rcevi
Business Interests
RCEVI offers a range of customized services, such as antiviral testing, validation of diagnostic kits, and vaccine/drug development. We have launched various products in Taiwan via out-licensing agreements and collaborate with research centers in Chang Gung University for high-quality R&D, emphasizing their core competencies in all the tests of viruses.
Contact Info
Shin-Ru Shih
Director/Distinguished professor
+886-3211-8800 ext.5497
srshih@mail.cgu.edu.tw
Kuei-Ching Hsiung
Postdoctoral Fellow
+886-3-2118800 ext.3041
kchsiung@gap.cgu.edu.tw